China Regenerative Medicine International Limited announced earnings results for the full year ended December 31, 2020. For the full year, the company announced sales was HKD 185.339 million compared to HKD 19.365 million a year ago. Net loss was HKD 404.226 million compared to HKD 395.006 million a year ago. Basic loss per share from continuing operations was HKD 0.18 compared to HKD 0.36 a year ago. Diluted loss per share from continuing operations was HKD 0.09 compared to HKD 0.149 a year ago.